Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma

The multinational phase 3 CLEAR study randomized patients with previously untreated advanced renal cell carcinoma to three arms: lenvatinib plus pembrolizumab versus lenvatinib plus everolimus versus sunitinib. The progression-free survival (primary end point) was significantly better in both combination arms compared with the sunitinib arm. The overall survival was longer with lenvatinib plus pembrolizumab than with sunitinib (HR 0.66; p=0.005) but was not longer with lenvatinib plus everolimus than with sunitinib (HR 1.15; p=0.30).